Literature DB >> 9737710

Cyclooxygenase in biology and disease.

R N Dubois1, S B Abramson, L Crofford, R A Gupta, L S Simon, L B Van De Putte, P E Lipsky.   

Abstract

Cyclooxygenase (COX), the key enzyme required for the conversion of arachidonic acid to prostaglandins was first identified over 20 years ago. Drugs, like aspirin, that inhibit cyclooxygenase activity have been available to the public for about 100 years. In the past decade, however, more progress has been made in understanding the role of cyclooxygenase enzymes in biology and disease than at any other time in history. Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and COX-2. Under many circumstances the COX-1 enzyme is produced constitutively (i.e., gastric mucosa) whereas COX-2 is inducible (i.e., sites of inflammation). Here, we summarize the current understanding of the role of cyclooxygenase-1 and -2 in different physiological situations and disease processes ranging from inflammation to cancer. We have attempted to include all of the most relevant material in the field, but due to the rapid progress in this area of research we apologize that certain recent findings may have been left out.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737710

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  515 in total

1.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

Authors:  Y Matsuoka; M Picciano; B Malester; J LaFrancois; C Zehr; J M Daeschner; J A Olschowka; M I Fonseca; M K O'Banion; A J Tenner; C A Lemere; K Duff
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Authors:  M C Walker; R G Kurumbail; J R Kiefer; K T Moreland; C M Koboldt; P C Isakson; K Seibert; J K Gierse
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

3.  Cytotoxic necrotizing factor from Escherichia coli induces RhoA-dependent expression of the cyclooxygenase-2 Gene.

Authors:  W Thomas; Z K Ascott; D Harmey; L W Slice; E Rozengurt; A J Lax
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors:  Iman H Bassyouni; Roba M Talaat; Tarek A Salem
Journal:  J Clin Immunol       Date:  2011-10-07       Impact factor: 8.317

5.  Increased cyclooxygenase activity impairs apoptosis of inflammatory neutrophils in mice lacking gelatinase B/matrix metalloproteinase-9.

Authors:  Elzbieta Kolaczkowska; Barbara Plytycz; Bernd Arnold; Helene Piccard; Ghislain Opdenakker
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

6.  COX-2 inhibitor reduces skeletal muscle hypertrophy in mice.

Authors:  Margaret L Novak; William Billich; Sierra M Smith; Kunal B Sukhija; Thomas J McLoughlin; Troy A Hornberger; Timothy J Koh
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-28       Impact factor: 3.619

Review 7.  [Interaction of anesthetics and analgesics with tumor cells].

Authors:  A Bundscherer; M Malsy; D Bitzinger; B M Graf
Journal:  Anaesthesist       Date:  2014-04       Impact factor: 1.041

8.  Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases.

Authors:  Qing Jiang; Xinmin Yin; Markus A Lill; Matthew L Danielson; Helene Freiser; Jianjie Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-11       Impact factor: 11.205

Review 9.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

10.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.